Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial

It brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. 

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *